Discovery of Multitarget-Directed Ligands against Alzheimer’s Disease through Systematic Prediction of Chemical–Protein Interactions
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
To determine chemical-protein interactions (CPI) is costly, time-consuming, and labor-intensive. In silico prediction of CPI can facilitate the target identification and drug discovery. Although many in silico target prediction tools have been developed, few of them could predict active molecules against multitarget for a single disease. In this investigation, naive Bayesian (NB) and recursive partitioning (RP) algorithms were applied to construct classifiers for predicting the active molecules against 25 key targets toward Alzheimer's disease (AD) using the multitarget-quantitative structure-activity relationships (mt-QSAR) method. Each molecule was initially represented with two kinds of fingerprint descriptors (ECFP6 and MACCS). One hundred classifiers were constructed, and their performance was evaluated and verified with internally 5-fold cross-validation and external test set validation. The range of the area under the receiver operating characteristic curve (ROC) for the test sets was from 0.741 to 1.0, with an average of 0.965. In addition, the important fragments for multitarget against AD given by NB classifiers were also analyzed. Finally, the validated models were employed to systematically predict the potential targets for six approved anti-AD drugs and 19 known active compounds related to AD. The prediction results were confirmed by reported bioactivity data and our in vitro experimental validation, resulting in several multitarget-directed ligands (MTDLs) against AD, including seven acetylcholinesterase (AChE) inhibitors ranging from 0.442 to 72.26 μM and four histamine receptor 3 (H3R) antagonists ranging from 0.308 to 58.6 μM. To be exciting, the best MTDL DL0410 was identified as an dual cholinesterase inhibitor with IC50 values of 0.442 μM (AChE) and 3.57 μM (BuChE) as well as a H3R antagonist with an IC50 of 0.308 μM. This investigation is the first report using mt-QASR approach to predict chemical-protein interaction for a single disease and discovering highly potent MTDLs. This protocol may be useful for in silico multitarget prediction of other diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking.
Mysinger, M. M., Carchia, M., Irwin, J. J., & Shoichet, B. K. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300687e · Cited by 2,412
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Assessing the accuracy of prediction algorithms for classification: an overview
Baldi, P., Brunak, S., Chauvin, Y., Andersen, C. A. F., & Nielsen, H. (2000) · Bioinformatics · doi:10.1093/bioinformatics/16.5.412 · Cited by 2,111
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Luo, H., Chen, J., Shi, L., Mikailov, M., Zhu, H., Wang, K., He, L., & Yang, L. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr299 · Cited by 206
Cited by
Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Gupta, R., Srivastava, D., Sahu, M., Tiwari, S., Ambasta, R. K., & Kumar, P. (2021) · Molecular Diversity · doi:10.1007/s11030-021-10217-3 · Cited by 1,473
“…of human copper trafficking blocker in cancer [369], identification of multi-target ligands through chemical-protein interaction in AD [370], prediction of the anticancer mechanism of Kushen Injection against Hepato-cellular carcinoma [371], and discovery of Pteridin-7(8H)- one-Based…”
BackgroundConcepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Neuroprotective activities of natural products from marine macroalgae during 1999–2015
Alghazwi, M., Kan, Y. Q., Zhang, W., Gai, W. P., Garson, M. J., & Smid, S. (2016) · Journal of Applied Phycology · doi:10.1007/s10811-016-0908-2 · Cited by 58
“As fucoidan is of significant structural diversity, it would be very interesting to investigate the structure-activity relationship, furthering rational design and modification of fucoidan towards efficient clinical development (Fang et al. 2015).”
BackgroundArtificial intelligence for dementia drug discovery and trials optimization
Doherty, T., Yao, Z., Khleifat, A. A. L., Tantiangco, H., Tamburin, S., Albertyn, C., Thakur, L., Llewellyn, D. J., Oxtoby, N. P., Lourida, I., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.13428 · Cited by 48
Metadata
- Authors
- Fang, J., Li, Y., Liu, R., Pang, X., Li, C., Yang, R., He, Y., Lian, W., Liu, A.-L., & Du, G.-H.
- Venue
- Journal of Chemical Information and Modeling
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-01-13
- Volume
- 55
- Issue
- 1
- Pages
- 149-164
- ISSN
- 1549-9596 (ISSN-L)
- 1549-960X
- OpenAlex
- W2029757179
- Cited by
- 118
- References
- 6
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.